Scientific-production Association “Microgen” has concluded the agreement with JSC “Biomed” them. I. I. Mechnikov (member of JSC “Pharmstandard”) about acquisition of rights on 31 name of diagnostic and therapeutic allergens. This will allow you to organize in Russia the production of new drugs against allergies on the advanced technology.
Following the transaction, the company’s portfolio will be doubled and will include the widest in Russia range of preparations of allergens. Under the agreement, the parties also agreed to transfer technology, production capacity of the branch of NPO “Microgen” in Stavropol. The plant will produce diagnostic, therapeutic, and diagnostic preparations for carrying out ASIT – allergen-specific immunotherapy.
It is expected that production in Stavropol will be launched in the next two years. After signing the agreement, the proportion of NPO “Microgen” in the market of drugs for ASIT will increase to 50% in real terms, said the Deputy General Director of “national immunobiological company,” Philip Pershkov. Currently, the NPO Microgen produces more than 30 kinds of allergens, allergoids and mixed allergens of pollen of trees and herbs.
In 2019 “national immunobiological company” and Institute of immunology FMBA of Russia signed a cooperation agreement. The competence of the parties will be used for further improvement of the production technology for the diagnosis and treatment of allergic diseases.
“In partnership with “national immunobiological company” we aim to upgrade the domestic production of allergens for diagnosis and treatment of allergies, including preparations for allergen-specific immunotherapy. Given the fact that about 30% of the population of the Russian Federation those or other manifestations of Allergy, the establishment of modern production of allergens and preparations on their basis for diagnosis and treatment is an important strategic task”, – added the Director of fgbu “SSC immunology Institute” FMBA of Russia Musa Khaitov.